Meticulous Research®—a leading global market
research company, published a research report titled, “North
America NGS Market by Offering (Kits [Library Prep, QC, DNA
Extraction], System) Type (Genome, Targeted) Application (Reproductive,
Oncology, Infectious) Technology (SBS, Nanopore, SMRT Seq) - Forecast to 2030.”
According to this latest publication from
Meticulous Research®, the North America NGS Market is expected to reach $13.7
billion by 2030 at a CAGR of 16% from 2023 to 2030.The growth of the North
America NGS market is attributed to several factors, including the rising
prevalence of cancer, the increasing utilization of NGS in cancer research and
treatment, the declining costs of sequencing procedures, advancements in
sequencing technologies, the rising investments in pharmaceutical R&D, the
increase in genome mapping programs, and the improvements in regulatory and
reimbursement frameworks for NGS-based diagnostic tests. However, the high
costs of NGS systems and consumables, the availability of alternative
technologies, the low chances of identifying positive, actionable mutations for
precision medicine, and ethical and legal issues related to NGS-based diagnosis
restrain the growth of this market.
Download Sample PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5607?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-09-2023
The increasing applications of NGS, the rising
adoption of bioinformatics and genomic data management solutions, and
government initiatives supporting large-scale genomic sequencing projects are
expected to create growth opportunities for the players operating in the North
America NGS market. However, the lack of skilled professionals and regulatory
& standardization concerns in diagnostic testing are major challenges to
market growth.
The increasing demand for NGS automation, the
development of portable sequencing technologies, and increasing partnerships
and collaborations among NGS instrument manufacturers to expand and improve
product offerings are prominent trends in the North America next-generation
sequencing market.
Key Players
The key players operating in the North America NGS
market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F.
Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer, Inc. (U.S.), Qiagen N.V.
(Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of
California, Inc. (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc.
(U.S.), Oxford Nanopore Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.),
and Beijing Genomics Institute (BGI) (China).
North America NGS Market: Future Outlook:
The North America NGS market study presents
historical market data in terms of values (2021 and 2022), estimated current
data (2023), and forecasts for 2030. The North America NGS Market is segmented
based on Offering (Consumables [Sample Preparation Consumables {DNA Extraction
and Amplification, Library Preparation & Target Enrichment, Quality
Control}, Other Consumables], NGS Platforms/Instruments, Software, Services),
Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing, Whole Exome
Sequencing, Other Sequencing Types), Technology (Sequencing by Synthesis, Ion
Semiconductor Sequencing, Single-molecule Real-time Sequencing (SMRT), Nanopore
Sequencing, DNA Nanoball Sequencing), Applications (Clinical Applications
[Reproductive Health, Oncology, Infectious Diseases, Other Clinical
Applications], Research and Other Applications [Drug Discovery, Agriculture
& Animal Research, Other Research Applications), End User (Hospitals and
Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic
Institutes & Research Centers, Other End Users), and Country. The study
also evaluates industry competitors and analyzes the market at the country
level.
Request Free Sample PDF @https://www.meticulousresearch.com/request-sample-report/cp_id=5607?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-09-2023
Among the offerings, in 2023, the consumables
segment is expected to account for the largest share of the North America NGS
market. The recurring use of consumables, rising demand for NGS-based
diagnostic tests, and the increasing applications of NGS in oncology,
reproductive health diagnosis, and drug discovery are increasing the demand for
consumables.
Among the sequencing types, in 2023, the targeted
genome sequencing segment is expected to account for the largest share of the
North America NGS market. The large share of this segment is mainly attributed
to its cost-effectiveness, its utilization in discovering somatic mutations in
intricate samples like cancerous tumors mixed with germline DNA, and the
substantial interest of researchers in utilizing targeted genome sequencing for
exploring gene-drug associations.
Based on technology, the market is segmented into
sequencing by synthesis, ion semiconductor sequencing, Single-molecule
Real-time Sequencing (SMRT), nanopore sequencing, and DNA nanoball sequencing.
Among these, the sequencing by synthesis segment is expected to account for the
largest share of the North America NGS market in 2023. The large share of this
segment is primarily attributed to the high accuracy of this technology in DNA
sequencing, its capacity for high-yield error-free throughput, and its increasing
integration within NGS products.
Among the applications, in 2023, the research and
other applications segment is expected to account for the largest share of the
North America NGS market. The growing prevalence of genetic disorders, the
increasing adoption of sequencing-based tests in laboratories, the growing
demand for personalized medicines, and the increasing NGS-based research are
factors contributing to the significant market share of this segment.
Speck to our analyst @https://www.meticulousresearch.com/speak-to-analyst/cp_id=5607?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-09-2023
Among the end users, in 2023, the pharmaceutical
& biotechnology companies’ segment is expected to account for the largest
share of the North America NGS market. The large market share of this segment
is attributed to factors such as the increasing R&D spending by
pharmaceutical & biotechnology companies and the rising incidence of
chronic diseases, which drive the adoption of NGS among pharmaceutical &
biotechnology companies.
Geographic Review
The North America NGS market is segmented into the
U.S. and Canada. The U.S. is estimated to account for the larger share of the
NGS market in 2023. The significant market share is primarily attributed to the
increasing R&D investments within the pharmaceutical and biotechnology
sector, the presence of key NGS market players in the country, supportive
governmental programs for genomics research, the growing applications of
NGS-based studies, the rising awareness about NGS-based tests, the rising incidence
of cancer and genetic disorders, and the favorable reimbursement landscape in
the U.S.
This research report provides a comprehensive
analysis of the NGS market in North America (U.S. and Canada).
Download Sample PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5607?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-09-2023
Key Findings of the North America NGS
Market Study:
Among the Offerings, in 2023, the
Consumables Segment is Estimated to Account for the Largest Share of the Market
in North America
The North America NGS market is segmented into
consumables, NGS platforms/instruments, software, and services. In 2023, the
consumables segment is expected to account for the largest share of the North
America NGS market. The large market share of this segment is attributed to
recurring demand for consumables and the rising adoption of NGS technology for
clinical and research purposes.
The Targeted Genome Sequencing Segment
is Estimated to Account for the Largest Share of the Market in North America
Based on sequencing type, the North America
NGS market is segmented into targeted genome sequencing, whole genome
sequencing, whole exome sequencing, and other sequencing types. In 2023, the
targeted genome sequencing segment is expected to account for the largest share
of the North America NGS market. The large market share of this segment is
attributed to low sequencing costs compared to other sequencing technologies,
higher sensitivity of the technique to call variants, and proven results in
identifying primary immunodeficiencies and specific gene-associated diseases.
In 2023, the Sequencing by Synthesis
Segment is Estimated to Account for the Largest Share of the Market in North
America
Based on technology, the North America NGS
market is segmented into sequencing by synthesis, ion semiconductor sequencing,
single-molecule real-time sequencing (SMRT), nanopore sequencing, and DNA
nanoball sequencing. In 2023, the sequencing by synthesis segment is expected
to account for the largest share of the North America NGS market. The large
market share of this segment is attributed to the high accuracy in delivering
base-by-base sequencing offered by the sequencing by synthesis method. This approach
minimizes sequence-specific errors, ensuring strong base calling across the
entire genome, including repetitive sequences and homopolymers.
The Research and Other Applications
Segment is Estimated to Account for the Largest Share of the Market in North America
Based on application, the research and other
applications segment is estimated to account for the largest share of the North
America NGS market. The large market share of this segment is attributed to the
increasing utilization of NGS in diverse research fields such as oncology,
agriculture, and other areas. Furthermore, the benefits of genetic research and
testing facilitated by NGS technology and the rising cancer incidence
contribute to this segment’s significant market share.
The Pharmaceutical & Biotechnology
Companies Segment is Estimated to Account for the Largest Share of the North
America NGS Market in 2023
The large share of this segment is primarily
attributed to the increasing adoption of advanced technologies for research
purposes and the increasing utilization of NGS for drug discovery.
U.S.: Fastest-growing Market in North
America
The market in the U.S. is expected to register
the highest CAGR during the forecast period. The market growth in the U.S. is
attributed to factors such as the growing demand for NGS-based diagnosis, the
increasing demand for NGS data among healthcare professionals for treatment
purposes, and the rising prevalence of cancer. Additionally, the increasing
adoption of NGS for precision medicine and the utilization of NGS technology
across diverse research domains contribute to the market’s growth in the U.S.
Download Sample PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5607?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=06-09-2023
Key questions answered in the report:
Which are the high-growth market segments in terms
of offering, sequencing type, technology, application, end user, and country?
What was the historical market for NGS across North
America?
What are the market forecasts and estimates for the
period 2023–2030?
What are the major drivers, restraints, challenges,
opportunities, and trends in the North America NGS market?
Who are the major players in the North America NGS
market?
